Morehouse School of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Morehouse School of Medicine sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 5 currently recruiting 7 completed early-phase tilt top decile by trial count

Morehouse School of Medicine: 13 sponsored US clinical trials, 5 recruiting.

Morehouse School of Medicine sponsors 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Uncontrolled Diabetes, with 1 trials.

Top-decile sponsor footprint

Morehouse School of Medicine ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the Morehouse School of Medicine pipeline

5 recruiting of 13 indexed (38% open); 7 completed (54%).

Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Uncontrolled Diabetes (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Morehouse School of Medicine: open-pipeline peers nationwide

Peers matched on 13 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Morehouse School of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1020304050 0%10%20%30%40%50% Total trials Recruiting share Morehouse School of MedicineAdaptimmuneAgennixAkili Interactive LabsAlumisNortheastern UniversityThomas HopeWilliam StoopsXenon Pharmaceuticals
Morehouse School of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Morehouse School of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

What to do with this Morehouse School of Medicine page

13 registered trials is a research-attention snapshot, not an endorsement of Morehouse School of Medicine or any single study.

  • 5 of Morehouse School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Uncontrolled Diabetes is the condition Morehouse School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Uncontrolled Diabetes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Morehouse School of Medicine pipeline card: 13 registered trials from official public datasets.Report a data error.